Group organizing Idaho abortion-rights initiative files lawsuit over ballot language
The group organizing a 2026 ballot initiative to restore abortion rights in Idaho is asking the state Supreme Court to order the attorney general and other state agencies to fix language it says is biased and misleading about what the initiative will do and how much it will cost taxpayers.
Idahoans United for Women and Families filed the lawsuit Thursday night. Idaho has a citizen ballot initiative process, but only its Legislature can propose constitutional amendments, unlike many other states. So instead of a constitutional amendment, the voters are asked to approve a citizen-crafted piece of legislation to be adopted. The measure requires a simple majority of voters to pass.
As part of the initiative process, the Idaho Attorney General's Office is responsible for drafting short and long ballot titles that summarize what the legislation would do if passed. Idaho law states that the language must describe the proposal accurately and use common language without phrasing that is likely to prejudice voters.
Idahoans United announced it would pursue the initiative in April 2024, and filed four proposed policies for approval in August. After that, the group moved forward with one proposed policy that would establish a fundamental right to contraception and fertility treatments under Idaho law, including in vitro fertilization, to make decisions about pregnancy and childbirth, and legalizing abortion before fetal viability, as well as preserving the right to abortion after viability in medical emergencies. Fetal viability would be determined by a physician and what treatment is available, but the commonly accepted gestational age of viability in the medical community is 23 to 24 weeks.
In the lawsuit, the group contends that the short ballot title includes the term 'fetus viability,' which is not the medical phrase, and conflicts with the term fetal viability being used in the long title. Melanie Folwell, Idahoans United's spokesperson, said the short title also left out that the law would provide for abortions in medical emergencies after viability.
The bigger issue, Folwell said, is with the fiscal impact statement, which is required to be drafted by the Idaho Division of Financial Management, to determine if the new law would cost taxpayer dollars.
As written, the statement says the laws affected by the initiative would not impact income, sales or product taxes and have no effect on the general fund. But it goes on to say it could change state expenditures in minor ways.
'Costs associated with the Medicaid and prisoner populations may occur,' it says, citing Idaho Code. 'Passage of this initiative is likely to cost less than $20,000 per year. The Medicaid budget for providing services was about $850 million in FY2024. If passed, nominal costs in the context of the affected total budget are insignificant to the state.'
Dan Estes, spokesperson for Idaho Attorney General Raúl Labrador's office, said they had no comment, citing pending litigation. Reclaim Idaho, a group that pursued an initiative to change Idaho's primary and general election system in 2023, sued over similar issues with their ballot language and ultimately prevailed.
The complaint filed in Idaho Supreme Court calls the statement biased and says it includes contradictory language, 'wrongly implies' that Medicaid and corrections spending would increase, and 'prejudicially includes an irrelevant reference to the state's $850 Medicaid budget.'
The statement in compliance with Idaho Code, the complaint says, should read that there is no financial impact to state or local governments.
The lawsuit includes public records that Folwell requested and received showing email exchanges between Juliet Charron, deputy director of Medicaid and Behavioral Health at the Idaho Department of Health and Welfare, and Greg Piepmeyer, chief economist at the Idaho Division of Financial Management, as well as Lori Wolff, chief administrator at DFM. Wolff is named as a defendant in her capacity as administrator.
States Newsroom has reached out to Charron, Piepmeyer and Wolff's office for comment.
The emails indicate there would be no impact to the general fund, but one email from Piepmeyer details the possible effects for the female prison population, including the 'rate of pregnancy occurring due to events within prison, and the rate at which each of these is already ascribed to rape or incest.'
'None of these are ones into which DFM ought to wade,' Piepmeyer's email said. 'Similar considerations apply to the Medicaid population, but with (probably reasonably) different rates.'
The lawsuit includes a motion to expedite, with a request that a final ruling be issued by the Idaho Supreme Court by April 15. The group has to gather at least 70,725 signatures by April 30, 2026, to qualify for the ballot.
The Idaho Supreme Court will determine whether to hear the case in the coming days. If so, and if the motion to expedite is granted, an initial hearing would likely take place within the next month, Folwell said.
1-30-25 Declaration of Melanie Folwell 1-30-25 Verified Petition for Writs of Certiorari & Mandamus
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNBC
21 minutes ago
- CNBC
Trump's drug price ultimatum sets pharma firms scrambling
Pharmaceutical firms are scrambling to respond to a fresh ultimatum from U.S. President Donald Trump demanding "binding commitments" to lower their drug prices stateside . The White House said Thursday that President Trump had sent letters to 17 major pharmaceutical firms outlining the steps they must take to lower the price of U.S. prescription drugs to "most favored nation" (MFN) levels by Sept. 29. They were told that if they "refuse to step up," the government will deploy every tool in its "arsenal to protect American families from continued abusive drug pricing practices," without stating what those measures could be. The companies to receive letters were AbbVie , Amgen , AstraZeneca , Boehringer Ingelheim, Bristol-Myers Squibb , Eli Lilly , EMD Serono, Roche' s subsidiary Genentech, Gilead , GSK , Johnson & Johnson , Merck , Novartis , Novo Nordisk , Pfizer , Regeneron and Sanofi . Healthcare stocks tumbled Friday, following broader market losses as investors digested Trump's amended trade tariffs. Shares of Wegovy-maker Novo Nordisk dropped 5% in early morning trade before paring losses to trade 1.3% lower at 11:15 a.m. London time (6:15 a.m. ET). Companies were informed that they must provide MFN prices to all Medicaid patients, the U.S. health program for low-income patients. They were also told not to offer medicines to other developed markets at better prices than those offered in the U.S., and that they should sell drugs directly to U.S. patients, thereby cutting out pharmacy middlemen known as pharmacy benefit managers (PBMs). Trump has long lambasted pharmaceutical firms for what he dubs are unfair pricing practices, previously saying that he planned to bring down U.S. prices by 80%. In May, the president signed an executive order to lower drug costs by tying the prices of some medicines in the U.S. to the significantly lower ones abroad under the MFN policy. The U.S. consistently pays the most in the world for many prescription drugs, due in part to the U.S.′ highly complex and fragmented reimbursement system and lack of national pricing control. The latest announcement comes as the pharmaceutical industry is also calling for clarity on potential industry-wide tariffs. Trump previously warned these could run as high as 200%. Many companies have nevertheless shared that they agree with some of Trump's concerns. AstraZeneca CEO Pascal Soriot said Tuesday that the Anglo-Swedish firm had been liaising closely with the U.S. administration over the MFN policy and investment in U.S. manufacturing more broadly. Last week, it announced plans to invest $50 billion in the U.S., following a slew of other pharma firms. "There are issues around prices. I personally believe the president is right to say price equalization should happen," Soriot told reporters on an earnings call. Vas Narasimhan, CEO of Swiss-headquartered Novartis, also said last month that the firm was pursuing an MFN policy to lower U.S. drug prices. JPMorgan analysts said in a note Friday that while the latest announcement was intended to serve as a stark warning, ongoing talks between with the U.S. administration could buy pharma firms some time to respond. "While the government's latest announcement may appear harsh, we think it is likely that the matter is being discussed to some extent between the companies and the government, and we believe no changes that would have a significant negative impact on pharmaceutical companies will occur in the short term," analysts led by Seiji Wakao said in a note to clients.

USA Today
an hour ago
- USA Today
'Rage Against the Regime' protests planned against Trump. Why on JD Vance's birthday?
The protests across the United States also fall on Vice President JD Vance's birthday. Tens of thousands of people are expected to gather nationwide on Saturday, Aug. 2 to ‒ as organizers have dubbed it ‒ 'Rage Against the Regime' of President Donald Trump. Organizers say the demonstrations, the latest in a series of peaceful summertime protests in hundreds of locations across the country, are meant to mobilize masses of people against the administration's actions. They are particularly concerned about aggressive immigration enforcement, dismantling of government programs and agencies from Medicaid to the National Weather Service, and attacks on democratic institutions, according to a news release. They also want to draw attention to the Trump administration's refusal to release more information about deceased child sex predator Jeffrey Epstein. The name of this day of protest is both a play on the name of the American rock band Rage Against the Machine, and an expression of public frustration. 'People don't know what to do with their rage,' Hunter Dunn, a national spokesperson for the 50501 protest group, which is organizing the rally, told USA TODAY. 'Let's give them something productive.' In June, people demonstrated in 2,100 locations as part of the 'No Kings' protests, scheduled to coincide with both President Donald Trump's 79th birthday and the military parade honoring the Army's 250th anniversary. They argued that the president was taking too much power for himself, directly contradicting the nation's original purpose, declaring independence from the King of England. On July 17, protesters took to the streets in 1,600 cities and towns for 'Good Trouble' demonstrations honoring the late Georgia Congressman John Lewis, a Democrat and former civil rights activist, who argued that people should get into "good trouble" by peacefully protesting social ills. Saturday is also Vice President JD Vance's 41st birthday, though Dunn said most organizers hadn't considered Vance in setting the date on the first Saturday of August. The White House referred questions about the protests to Vance's office. A spokesperson for Vance didn't immediately respond to USA TODAY's request for comment. The band Rage Against the Machine, which played from 1991 until disbanding in 2024, was known for its leftist politics, including anti-capitalist and anti-authoritarian messages. USA TODAY reached out to the band for comment but did not get an immediate reply. In Kansas, 50501 event coordinator Scott McFarland said he had never heard of the band. He sees the protest he's organizing for outside the state Capitol in Topeka, as both an outlet for people to express their anger and to show them they aren't alone in what he called an autocratic society seeking to divide Americans. A Massachusetts protest is billed as a 'festival of nonviolent resistance." At Cambridge Common, near Harvard University, the festival includes music, ice cream and art, and also calls for action, including mutual aid to help immigrant rights and learning about boycotting, a a news release said. 'It starts at a very local and personal level, and then becomes a collective thing,' Samantha McGarry, a local volunteer, said. 'Over time, the hope is that it kind of weakens the pillars that are upholding an authoritarian regime using nonviolent measures.' Dunn, of 50501, said there are upwards of 400 "Rage Against the Regime" demonstrations planned ‒ far fewer than the 1,500 "Good Trouble" protests.

Washington Post
an hour ago
- Washington Post
Medicare, Medicaid plans to experiment with covering weight loss drugs
Some obese Americans on Medicare and Medicaid could get access to expensive weight loss drugs under a five-year experiment being planned by the Trump administration. Under the proposed plan, state Medicaid programs and Medicare Part D insurance plans will be able to voluntarily choose to cover Ozempic, Wegovy, Mounjaro and Zepbound for patients for 'weight management' purposes, according to Centers for Medicare and Medicaid Services documents obtained by The Washington Post.